Lexaria and Neutrisci Enter Global Licensing Agreement Kelowna, British Columbia

Lexaria and Neutrisci Enter Global Licensing Agreement

Kelowna, British Columbia February 26, 2018 Lexaria

Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ) a drug

delivery platform innovator, announces it has entered an agreement with

NeutriSci International Inc. ("NeutriSci") (TSX-V: NU, OTCQB: NRXCF) such that

NeutriSci now owns 100% of Ambarii Trade Corporation ( Ambarii ), and Lexaria

has granted to NeutriSci an Intellectual Property License and Supply Agreement

(the License Agreement ) for the manufacturing and sale of CBD based products.

Under the License Agreement, NeutriSci will continue the

development and sales of its proprietary sublingual mouth-melt consumer products

that incorporate Lexaria s technology for enhancing palatability and

bioavailability of beneficial non-psychoactive cannabinoids in NeutriSci s

existing and pipeline product formats. Lexaria will earn ongoing royalty

revenues from the sales generated by these products.

The relationship between our companies has evolved in a

positive fashion and allows us each to focus on our core competencies which

should benefit all stakeholders, commented Chris Bunka, Lexaria CEO. Neutrisci

has developed a unique form factor that can now be empowered with Lexaria s

complementary technology which also allows consumers everywhere to benefit.

We are very pleased to announce this long-term licensing and

development agreement with Lexaria, commented Glen Rehman, NeutriSci President.

This agreement will allow NeutriSci to focus on the global distribution of our

proprietary CBD product line while letting Lexaria focus on licencing and

development. This change to our business relationship is a win-win for both

Separately, the Company also announces the exercise of warrants

and options previously granted. The Company has received for exercise a total of

46,266 warrants with an exercise price of US$0.60. The Company has also received

for exercise 50,000 stock options with an exercise price of US$0.2273. The

warrant and option exercises are by third parties who are neither officers nor

directors of the Company.

Following this issuance there will be 71,097,305 Common shares

of the Company issued and outstanding. The Company received proceeds of

$39,124.60 from the exercise of these warrants and options. No commissions or

placement fees have been paid related to the funds received from these warrants

exercised. Proceeds will be used for general corporate purposes.

The securities referred to herein will not be or have not

been registered under the United States Securities Act of 1933, as amended, and

may not be offered or sold in the United States absent registration or an

applicable exemption from registration requirements.

Lexaria Bioscience Corp. has developed

and out-licenses its disruptive delivery technology that promotes healthier

ingestion methods, lower overall dosing and higher effectiveness of lipophilic

active molecules. Lexaria has multiple patents pending in over 40 countries

around the world and has patents granted in the USA and in Australia for

utilization of its DehydraTECHTM delivery technology. Lexaria s

technology provides increases in intestinal absorption rates; more rapid

delivery to the bloodstream; and important taste-masking benefits, for orally

administered bioactive molecules including cannabinoids, vitamins, non-steroidal

anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements

which are not historical facts are forward-looking statements. The Company makes

forward-looking public statements concerning its expected future financial

position, results of operations, cash flows, financing plans, business strategy,

products and services, competitive positions, growth opportunities, plans and

objectives of management for future operations, including statements that

include words such as "anticipate," "if," "believe," "plan," "estimate,"

"expect," "intend," "may," "could," "should," "will," and other similar

expressions are forward-looking statements, including but not limited to: that

any additional patent protection will be realized or that patent achievements

will deliver material results. Such forward-looking statements are estimates

reflecting the Company's best judgment based upon current information and

involve a number of risks and uncertainties, and there can be no assurance that

other factors will not affect the accuracy of such forward-looking statements.

Factors which could cause actual results to differ materially from those

estimated by the Company include, but are not limited to, government regulation,

managing and maintaining growth, the effect of adverse publicity, litigation,

competition, scientific discovery, the patent application and approval process

and other factors which may be identified from time to time in the Company's

public announcements and filings. There is no assurance that existing capital is

sufficient for the Company's needs or that it will be able to raise additional

capital. There is no assurance the Company will be capable of developing,

marketing, licensing, or selling edible products containing cannabinoids or any

other active ingredient, or that the Biolog license agreement will successfully

produce benefits to the Company. There is no assurance that any planned

corporate activity, scientific research or study, business venture, technology

licensing pursuit, patent application or allowance, consumer study, or any

initiative will be pursued, or if pursued, will be successful. There is no

assurance that any of Lexaria s postulated uses, benefits, or advantages for the

patented and patent-pending technology will in fact be realized in any manner or

in any part. No statement herein has been evaluated by the Food and Drug

Administration (FDA). Lexaria-associated products are not intended to diagnose,

treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility

for the adequacy or accuracy of this release.